Agritek Launches Of MicroDose Oral Strips Brand

Cannabis Investing News

Agritek Holdings announced the launch and first order for its licensed brand “MicroDose” oral strips for the medicinal market of California.

Agritek Holdings (OTCQB:AGTK) announced the launch and first order for its licensed brand “MicroDose” oral strips for the medicinal market of California.

As quoted in the press release:
Agritek Holdings will provide the licensing and packaging to produce the exclusive line of 10mg and 50 mg oral strips as a medicinal alternative for patients. The Agritek “Microdose” brand will be produced and distributed through its permitted manufacturer and collective to multiple dispensaries throughout California. AGTK will receive a flat fee per single package designed exclusively by Agritek Holdings with the first 10,000 units being delivered by the end of July.
The new Microdose Strips (www.microdosestrips.com) are a discreet, dose controlled, evaporating oral strip which offer a unique and smoke-free alternative to patients initially residing and holding medical recommendations in California. The medicated oral strips will be distributed to dispensaries and sold in a single pack. Doses for one oral strip will consist of 10mg and 50mg strips, and are manufactured through a consistent organic sun growth cannabis base. The strip is utilized by placed under the tongue or between the cheek and gum of the mouth with the strip dissolving directly into the bloodstream. The Microdose Strips designed exclusively for Agritek will be available in Indica and Sativa strains and will eventually be launched nationally as a CBD brand through licensed manufacturers. As previously stated, Agritek will receive a flat fee for brand license and package, with distribution and manufacturing being fulfilled through its’ licensed manufacturer in California. The product will sell for between $8.00 and $12.00 depending on dose to dispensaries with Agritek receiving a flat fee royalty for packaging and brand name.

Click here to read the full press release.

The Conversation (0)
×